Exosomes for Hair Loss: 2026 Hype vs Evidence

Plausible biology, thin clinical data, premium pricing. The honest 2026 read on exosome therapy for hair loss and where it actually fits.

Plausible biology, thin clinical data, premium pricing. The honest 2026 read on exosome therapy for hair loss and where it actually fits.

TRT does not cause hair loss in non-predisposed men. It accelerates AGA in men who carry the predisposition. The trade-off is real, the management is well-defined, and the men who lose the most are the ones who treated the math as an afterthought.

Platelet-rich plasma works in mild-to-moderate AGA when properly administered. Effect tier similar to topical minoxidil. Protocol variability drives outcome variability between clinics.

Low-level laser therapy produces real but modest hair count gains in randomized sham-controlled trials. Here is where LLLT genuinely fits in a serious hair loss protocol, and where the marketing oversells the data.

Scalp massage has a plausible mechanism and one small study supporting modest effects. The right place is as a daily 4-5 minute adjunct, not a primary therapy.

Rosemary oil produced effects similar to 2 percent minoxidil at six months in Panahi 2015. Real but smaller than the headline implies. Where it actually fits in a hair loss protocol.

Saw palmetto inhibits 5-alpha reductase weakly. Finasteride inhibits it strongly. When the natural alternative actually fits the protocol, and when it does not.

Microneedling is the most evidence-backed adjunct in hair loss, and also the one most men do wrong. Three mistakes flatten results: depth too shallow, frequency too high, and using it as standalone instead of a delivery system.

Topical finasteride is sold as the safer, milder, more local version of the oral pill. The pharmacokinetic data does not support that framing as cleanly as the marketing implies. Evidence-based guide to what topical actually delivers.

Dutasteride suppresses DHT more aggressively than finasteride, but its 4-5 week half-life and broader receptor inhibition reshape the entire risk-benefit conversation. Evidence-based guide on when switching actually makes sense.